{"entity":{"id":"nct07011823","kind":"trial","name":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","aka":["KEY-MELT"],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Gangnam Severance Hospital, not yet recruiting.","summary":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC is a phase 2, interventional study registered as NCT07011823 by Gangnam Severance Hospital, with a registry enrolment figure of 20 participants, started 2025-07-16 and due to reach its primary completion in 2027-07-31. Interventions recorded: Partial breast-irradiation. Conditions listed: Triple-Negative Breast Neoplasm. Triple-negative eligibility wording from the registry: \"* Patients with triple-negative breast cancer confirmed on tissue biopsy\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07011823","url":"https://clinicaltrials.gov/study/NCT07011823"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07011823","phase":"2","setting":"Phase II Trial of Immunochemotherapy and Partial Breast Irradiation in Early TNBC With Immune-cold Tumor Environment (KEY-MELT)","sponsor":"Gangnam Severance Hospital","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07011823/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}